Acadia Pharmaceuticals (ACAD) Total Current Liabilities (2010 - 2026)

Acadia Pharmaceuticals has reported Total Current Liabilities for 17 years, with the latest figure at $305.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 0.99% year-over-year to $305.5 million; the trailing twelve-month figure through Mar 2026 stood at $305.5 million (up 0.99% YoY), and the FY2025 full-year result was $277.1 million, down 29.82% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $305.5 million, up from $277.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $394.9 million in Q4 2024, with the low at $116.6 million in Q3 2022.
• Average Total Current Liabilities over 5 years is $255.0 million, with a median of $277.1 million recorded in 2025.
• Year-over-year, Total Current Liabilities jumped 102.38% in 2023 and retreated 29.82% in 2025.
• Tracing ACAD's Total Current Liabilities over 5 years: stood at $125.6 million in 2022, then jumped by 102.38% to $254.3 million in 2023, then soared by 55.31% to $394.9 million in 2024, then dropped by 29.82% to $277.1 million in 2025, then advanced by 10.25% to $305.5 million in 2026.
• The last three Total Current Liabilities figures came in at $305.5 million (Q1 2026), $277.1 million (Q4 2025), and $356.6 million (Q3 2025), per Business Quant data.

Peer Comparison